Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSavills Regulatory News (SVS)

Share Price Information for Savills (SVS)

Share Price is delayed by 15 minutes
Get Live Data
808.00    -10.00 (-1.22%)
Bid:
811.00
Ask:
813.00
Spread: 2.00 (0.247%)
Market Cap: £1.12b
SVS Live PriceLast checked at - London Stock Exchange

Intraday Savills Share Chart

Director/PDMR Shareholding

21 Apr 2022 16:57

RNS Number : 9639I
Savills PLC
21 April 2022
 

SAVILLS PLC (THE "COMPANY")

TRANSACTION IN SHARES BY DIRECTORS AND PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMRS)

 

Vesting of Share Awards

 

Awards over ordinary shares of the Company under the Company's Deferred Share Plans have become unconditional in all respects following the end of their Deferred Period. In satisfaction of the Awards, the Trustees of the Group's Employee Benefit Trusts effected the transfer of shares, following the settlement of associated tax liabilities through the sale of shares, to Directors and PDMRs of the Company as follows:-

 

Director/ PDMR

Number of Shares Transferred

Number of Shares Disposed

Shareholding following this notification

Shareholding as a % of issued share capital

Mark Ridley (Director)

41,688

20,155

231,854

0.16%

Simon Shaw (Director)

62,189

62,189

182,579

0.13%

Chris Lee (PDMR)

13,285

6,423

119,000

0.08%

David Lipson (PDMR)

23,132

11,593

65,661

0.05%

Christian Mancini (PDMR)

10,445

-

147,685

0.10%

Mitchell Rudin (PDMR)

60,618

30,644

89,388

0.06%

James Sparrow (PDMR)

30,707

14,847

72,160

0.05%

 

The share price on disposal of all shares was £10.803843 per share.

 

Grant of Share Awards

 

The Company announces that on 20 April 2022 the grant of the share based element of 2021 profit share awards has been made under the Savills Deferred Share Bonus Plan to Directors and PDMRs as follows:-

 

Director/ PDMR

Number of shares subject to the Savills Deferred Share Bonus Plan awarded to the Director/ PDMR on 20 April 2022

Mark Ridley (Director)

90,045

Simon Shaw (Director)

67,328

Alex Jeffrey (PDMR)

99,473

Chris Lee (PDMR)

37,442

Raymond Lee (PDMR)

64,159

Christian Mancini (PDMR)

16,621

Mitchell Rudin (PDMR)

19,945

James Sparrow (PDMR)

36,529

 

The Company announces that on 20 April 2022 the grant of an award has been made under the Savills Deferred Share Plan to a PDMR as follows:-

 

PDMR

Number of shares subject to the Savills Deferred Share Plan awarded to the PDMR on 20 April 2022

Alex Jeffrey

45,662

Vesting on a sliding scale is dependent upon the satisfaction of performance criteria relating to the financial performance of Savills Investment Management, including the performance of funds managed by Savills Investment Management, over the period 2022 to 2024.

All the above awards have a Deferred Period of three years and are subject to rolled-up dividend shares whereby the number of shares awarded will be increased on the vesting date to reflect final and interim dividends declared during the Deferred Period.

The Company announces that on 20 April 2022 the grant of share awards under The Schedule to The Savills Deferred Share Plan to PDMRs based in the United States of America as follows:-

 

PDMR

Number of shares subject to the Savills Deferred Share Plan awarded to the PDMR on 20 April 2022

David Lipson (PDMR)

66,485

Mitchell Rudin (PDMR)

66,485

20% of Mr Lipson's award will vest on each of the five anniversaries subsequent to the date of grant subject to continued employment. 50% of Mr Rudin's award will vest from 31 December 2022 and 50% from 31 December 2023 subject to continued employment and performance. Both awards are subject to rolled-up dividend shares whereby the number of shares awarded will be increased on the vesting dates to reflect final and interim dividends declared during the Deferred Periods.

Resulting beneficial interests under the Savills Deferred Share Bonus Plan and Savills Deferred Share Plan further to the above notifications are as follows:

Director/ PDMR

Resulting beneficial interest under the Savills Deferred Share Bonus Plan and Savills Deferred Share Plan

Mark Ridley (Director)

199,417

Simon Shaw (Director)

148,896

Alex Jeffrey (PDMR)

347,459

Chris Lee (PDMR)

61,844

Raymond Lee (PDMR)

98,142

David Lipson (PDMR)

101,170

Christian Mancini (PDMR)

119,371

Mitchell Rudin (PDMR)

110,782

James Sparrow (PDMR)

91,620

 

The Company announces that on 20 April 2022 awards have been made under The Savills plc Performance Share Plan (the "Performance Share Plan") to Directors and PDMRs of the Company as follows:

 

Director / PDMR

Number of Shares subject to the Performance Share Plan awarded to the Director / PDMR on 20 April 2022

Total number of shares subject to the Performance Share Plan following this notification

Mark Ridley (Director)

56,803

266,276

Simon Shaw (Director)

43,397

211,999

Chris Lee (PDMR)

22,006

102,780

 

The Performance Share Plan provides for the award of nil cost options or conditional awards of ordinary shares in the Company.

Awards of shares are made subject to a three-year performance period. Awards which satisfy the applicable performance criteria (as below) in the three-year performance period will then vest after an additional two-year holding period.

Awards vest subject to the satisfaction of the following performance criteria measured over the three years to 31 December 2024:

(a) one-third of the initial value of an award is subject to the Company's Total Shareholder Return ('TSR') performance measured against the TSR of the FTSE Mid 250 Index (excluding investment trusts);

(b) a further one-third of the initial value of an award is subject to Group Earnings per Share ('EPS') performance; and

(c) the final one-third of the initial value of an award is subject to the three year average Return on Capital Employed ('ROCE') of the Company.

Awards vest as follows:

(a) for the TSR linked part of an award, 25% (i.e. threshold) will vest if the Company's TSR matches Index performance, rising to 100% (i.e. maximum) if the Company's TSR outperforms the Index by 8% p.a., compound with sliding scale vesting between the two points;

(b) for the EPS growth linked part of an award, 25% (i.e. threshold) will vest if the Company's EPS growth is 6% p.a., compound rising to 100% (i.e. maximum) if the Company's EPS growth is 12% p.a., compound with sliding scale vesting between the two points; and

(c) for the ROCE linked part of an award, 25% (i.e. threshold) will vest if the Company's ROCE is 15% p.a., rising to 100% (i.e. maximum) if the Company's ROCE is 25% p.a. or more; and with straight-line vesting between the two points.

 

The information set out below is provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation No 596/2014.

1.

Details of the Director/ PDMR

 

(a)

Name

1. Mark Ridley

2. Simon Shaw

3. Alex Jeffrey

4. Chris Lee

5. Raymond Lee

6. David Lipson

7. Christian Mancini

8. Mitchell Rudin

9. James Sparrow

 

2.

Reason for the notification

 

(a)

Position/ status

1. Group Chief Executive/ Director

2. Group Chief Financial Officer/ Director

3. Chief Executive Officer - Savills Investment Management/ PDMR

4. Group Legal Director and Company Secretary/ PDMR

5. Chief Executive - Hong Kong, Macau and Greater China/ PDMR

6. President - Savills North America/ PDMR

7. Chief Executive Officer Asia Pacific (ex-Greater China)/ PDMR

8. President, Savills North America/ PDMR

9. CEO, Savills UK & EMEA/ PDMR

 

(b)

Initial notification/ Amendment

 

Initial notification

3.

Details of the issuer

 

(a)

Name

Savills plc

 

(b)

LEI

213800WXICGMBWHTA933

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

(a)

Description of the Financial Instrument

 

Savills plc Ordinary Shares of 2.5p each

(b)

Identification code of the Financial Instrument

 

GB00B135BJ46

(c)

Nature of the transaction

 

1) Vesting of awards under the Company's Deferred Share Plans and sale of resultant shares

2) Grant of awards over Ordinary Shares in accordance with the Company's Deferred Share Bonus Plan and Deferred Share Plan

3) Grant of awards over Ordinary Shares in accordance with the Company's Performance Share Plan

 

(d)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

1)

Acquisition

£nil per share

 

 

 

 

 

 

 

Disposal

£10.803843 per share

1. 41,688

2. 62,189

3. n/a

4. 13,285

5. n/a

6. 23,132

7. 10,445

8. 60,618

9. 30,707

 

1. 20,155

2. 62,189

3. n/a

4. 6,423

5. n/a

6. 11,593

7. n/a

8. 30,644

9. 14,847

 

2)

£nil per share

1. 90,045

2. 67,328

3. 145,135

4. 37,442

5. 64,159

6. 66,485

7. 16,621

8. 86,430

9. 36,529

 

3)

£nil per share

1. 56,803

2. 43,397

3. n/a

4. 22,006

5. n/a

6. n/a

7. n/a

8. n/a

9. n/a

 

(e)

Aggregated information

 

- Aggregated volume

- Price

 

N/A

 

 

(f)

Date of the transaction

 

20 April 2022

(g)

Place of the transaction

 

Outside a trading venue

 

Name of contact and telephone number for queries:

Chris Lee

Group Legal Director & Company Secretary

020 3107 5444

 

21 April 2022

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKZGZDKMKGZZM
Date   Source Headline
2nd Dec 202410:00 amRNSTotal Voting Rights
26th Nov 20243:34 pmRNSHolding(s) in Company
22nd Nov 20242:00 pmRNSAdditional Listing
15th Nov 20242:58 pmRNSHolding(s) in Company
14th Nov 20241:53 pmRNSHolding(s) in Company
13th Nov 20241:47 pmRNSHolding(s) in Company
12th Nov 20242:51 pmRNSDirector/PDMR Shareholding
12th Nov 20242:48 pmRNSHolding(s) in Company
11th Nov 20242:25 pmRNSHolding(s) in Company
1st Nov 202411:00 amRNSTotal Voting Rights
14th Oct 20249:52 amRNSDirector/PDMR Shareholding
4th Oct 20242:00 pmRNSAdditional Listing
1st Oct 202411:00 amRNSTotal Voting Rights
18th Sep 20242:43 pmRNSDirector Declaration
16th Sep 20243:50 pmRNSDirector Declaration
12th Sep 20241:47 pmRNSDirector/PDMR Shareholding
2nd Sep 202411:00 amRNSTotal Voting Rights
29th Aug 20242:24 pmRNSDirector/PDMR Shareholding
15th Aug 202411:00 amRNSBlock listing Interim Review
13th Aug 20243:17 pmRNSDirector/PDMR Shareholding
8th Aug 20247:00 amRNSHalf-year Report
1st Aug 202411:00 amRNSTotal Voting Rights
30th Jul 20242:11 pmRNSHolding(s) in Company
22nd Jul 20242:36 pmRNSBlock listing Interim Review
11th Jul 20244:26 pmRNSDirector/PDMR Shareholding
1st Jul 20249:27 amRNSTotal Voting Rights
20th Jun 202410:36 amRNSDirector/PDMR Shareholding
13th Jun 20241:37 pmRNSDirector/PDMR Shareholding
11th Jun 20244:42 pmRNSDirector/PDMR Shareholding
7th Jun 20244:01 pmRNSDirector/PDMR Shareholding
4th Jun 20242:43 pmRNSDirector/PDMR Shareholding
3rd Jun 202411:00 amRNSTotal Voting Rights
23rd May 20242:21 pmRNSDirector/PDMR Shareholding
17th May 20243:44 pmRNSDirector/PDMR Shareholding
15th May 20243:06 pmRNSResult of AGM
15th May 202410:02 amRNSAGM Statement
14th May 20248:00 amRNSDirector/PDMR Shareholding
2nd May 20248:28 amRNSTotal Voting Rights
26th Apr 20242:13 pmRNSDirector/PDMR Shareholding
26th Apr 202411:21 amRNSDirector Declaration
15th Apr 20243:42 pmRNSDirector/PDMR Shareholding
12th Apr 20245:12 pmRNSDirector/PDMR Shareholding
8th Apr 20243:47 pmRNSAnnual Report and AGM Notice
21st Mar 20248:17 amRNSDirector/PDMR Shareholding
19th Mar 20245:11 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSNon-Executive Director Appointment
14th Mar 20247:00 amRNSFinal Results
13th Mar 20241:37 pmRNSDirector/PDMR Shareholding
15th Feb 202410:00 amRNSBlock listing Interim Review
13th Feb 20246:07 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.